s
61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals
24-05-2024, 14:09
STOCKHOLM, May 24, 2024 /PRNewswire/ — A pioneering study, presented today at the 61st ERA Congress, has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease. The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) study […] L'articolo 61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals proviene da La Ragione.
CONTINUA A LEGGERE
18
0
0
Guarda anche
La Ragione
01:43
Il Verona ribalta il Venezia e vince il derby 2-1
La Ragione
Ieri, 23:43
Il Napoli batte 3-1 il Como e conserva il primato solitario
La Ragione
Ieri, 21:43
Nuove nomine nel Consiglio di Amministrazione di AmCham Italy
La Ragione
Ieri, 21:43
Inaugurato a Catania e Palermo il Trofeo Coni Sicilia 2024
La Ragione
Ieri, 20:45